Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bis

Go back to Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bis
(NASDAQ: CBIO) Delayed: 13.17 +0.10 (0.77%)
Previous Close $13.07    52 Week High $4.57 
Open $13.16    52 Week Low $0.62 
Day High $13.81    P/E N/A 
Day Low $13.12    EPS $0.00 
Volume 250,371